The Cavity as a Lasting Abode for Tuberculous Bacilli

An Observational Study

Nadia Jawad^{1,2} · Saira Jafri^{1,2} · Nausheen Saifullah^{1,2} · Naseem Ahmed^{1,2}

Accepted: 10 December 2021 / Published online: 17 January 2022
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021

Abstract

The aim of this study was to determine the factors associated with persistent sputum positivity at the end of 2 months of treatment in patients presenting with (drug-susceptible) pulmonary tuberculosis at a tertiary care hospital in Karachi. A cross-sectional study was conducted at the Department of Chest Medicine (Ward 12), Jinnah Postgraduate Medical Center (JPMC), Karachi, over 6 months. A sample of 73 consenting, newly diagnosed, smear-positive drug-susceptible pulmonary tuberculosis patients was studied. Demographic (age, gender, height, weight and duration of tuberculosis, BMI, socioeconomic, occupational, marital, educational and residential statuses) and clinical factors (chest X-ray extent and cavities, initial smear results, diabetic and smoking statuses) which may be associated with sputum non-conversion were entered in a proforma. Patients were followed up at 2 months of treatment with a sputum smear. Data analysis was done on SPSS (Statistical Package for Social Sciences-version 20.0). Rate of sputum positivity after 2 months of anti-tubercular drug treatment was 17.8%. None of the above-mentioned demographic and clinical factors was associated with persistence of sputum positivity except for the presence of CXR cavities, which made it 5.5 times more likely that the patient would remain smear-positive at 2 months ($p=0.035$). The finding of chest radiograph cavities makes it highly likely that a pulmonary tuberculosis patient may remain infectious or have an unfavorable outcome despite taking treatment for 2 months. Clinicians and national policy-makers should thus bear in mind the implications this can have with regard to disease control and therefore pay particular attention to such patients in terms of stringent monitoring and directly observed treatment short-course (DOTS) provision.

Keywords Clinical factors · Drug-sensitive tuberculosis · Persistent positivity · Pulmonary tuberculosis · Smear-positive · Sputum smear

Abbreviations

AFB	Acid-fast bacilli
BMI	Body mass index
CI	Confidence interval
COVID-19	Coronavirus disease due to SARS CoV-2
CXR	Chest radiograph
DM	Diabetes mellitus
ESR	Erythrocyte sedimentation rate
HIV	Human immunodeficiency virus
IFN	Interferon

MDR	Multidrug resistant
OR	Odds ratio
PTB	Pulmonary tuberculosis
SPSS	Statistical Package for Social Sciences
TB	Tuberculosis
TTD	Time to detection
WHO	World Health Organization
XDR	Extensively drug resistant

Introduction

Tuberculosis (TB) continues to be a colossal public health challenge globally and remains one of the world's deadliest diseases, killing about 1.5 million and infecting about 10 million people worldwide in 2018 [1]. An untreated patient has the potential to infect another 10–15 people each year, depending upon bacillary load, duration of close contact,

This article is part of the Topical Collection on *Medicine*

✉ Saira Jafri
meetsaira@gmail.com

¹ Karachi, Pakistan

² Jinnah Postgraduate Medical Centre, Karachi, Pakistan

and duration of antitubercular treatment [2, 3]. On starting effective antitubercular treatment, bacillary load decreases rapidly, which correlate with reduced infectivity [4]. Therefore, infection control measures are recommended for all sputum smear-positive patients until serial smears convert to negative [5, 6].

Sputum microscopy for acid-fast bacilli serves as a well-validated and cost-effective means of measuring treatment response [7]. Non-conversion of sputum smear at the end of the second month of treatment has been documented to be associated with unfavorable outcomes such as failure and relapse within 2 years of follow-up [8, 9]. Several factors that correlate with heavy initial bacillary load (higher sputum smear and culture grading at diagnosis, shorter time to detection (TTD) of *Mycobacterium tuberculosis* on liquid cultures) and radiologically extensive disease have been linked with sputum smear/culture non-conversion at the end of the second month of TB treatment [10]. Additionally, increasing age, erythrocyte sedimentation rate (ESR), male sex, smoking, diabetes mellitus (DM), malnutrition, anemia, and thrombocytosis have also been associated with persistent sputum positivity [11, 12].

Through this study, we sought to determine the factors associated with persistent sputum positivity at the end of 2 months of treatment in patients with drug-sensitive pulmonary tuberculosis presenting to a tertiary care hospital in the metropolitan city of Karachi.

In the COVID era, co-infection with COVID-19 raises concerns about the interactions between the two diseases with respect to immune responses, morbidity, and mortality. SARS CoV-2 activates the adaptive immune response, with the CD4+ T cell response providing protective immunity [13]. In a patient with latent/active TB, co-infection may alter the course of COVID-19 disease. Though little is known about the exact immune responses at play in co-infected patients, evidence provided by a study performed on whole blood and bronchoalveolar lavage fluid suggest that active TB increases the risk of severe COVID-19 disease, due to increased abundance of circulating myeloid subpopulations and increased interferon (IFN) production [14].

The first ever global cohort of COVID-19 and active/former tuberculosis patients constituted 49 patients (42 had active TB and 7 had TB sequelae) recruited by the Global Tuberculosis Network (GTN) in 8 countries on 3 continents [15]. This observational study concluded that COVID-19 could occur before, after, or simultaneously with TB. No causal associations were established due to the small number of patients. Also, authors agreed that larger, longitudinal studies were required to definitively ascertain the role of COVID-19 in accelerating progression from latent to active TB and the impact of TB sequelae on COVID-19 outcomes.

The global TB and COVID-19 study by the GTN/WHO on nearly 700 patients in 40 countries is expected to clarify

many ambiguities on the interactions of the two diseases, including the risk of progression to active TB in those with latent TB [16].

TB/COVID-19 co-infection may spell poor outcomes, including higher mortality. Combined data from the 8 countries and Sondalo Hospital study show an 11.6% case fatality rate (8/69) [17]. The study shows that mortality may be more related to occurrence of comorbidities and older age than TB alone. However, higher death rates may occur in cases with resistant or severe forms of TB even in the young.

The COVID-19 pandemic has given rise to new fears about the fate of undiagnosed/unreported TB patients as access to TB care services has become limited. This is evidenced by a drop in TB notification rates [18]. High burden countries like Pakistan need to step up policies and invest in active case-finding strategies so that the success gained in terms TB mortality is not reversed.

Since our study was predominantly conducted before the pandemic took hold in Pakistan, we did not consider or test for COVID-19 among our enrolled patients.

Through this study, we sought to determine the factors associated with persistent sputum positivity at the end of 2 months of treatment in patients with drug-sensitive pulmonary tuberculosis presenting to a tertiary care hospital in the metropolitan city of Karachi.

Material and Methods

Study Design, Setting, and Duration

This cross-sectional study was conducted after an ethical approval (No. F.2–81/2019-GENL/21153/JPMC) at the Department of Chest Medicine (Ward 12), Jinnah Postgraduate Medical Center (JPMC), Karachi, over a period of about 6 months from September 14, 2019, to March 16, 2020.

Patients

Consenting adult patients aged 20–60 years of either gender (randomly selected among out-patients) with pulmonary infiltrate (opacity with or without air bronchogram) or cavity on chest radiograph along with persistent productive cough and fever (body temperature ≥ 37.8 °C) and confirmed by positive sputum smear on sputum microscopy for acid-fast bacilli (AFB) were included and labeled as having *pulmonary tuberculosis*. Patients who did not give consent and had history of hepatitis C and B or human immunodeficiency virus (HIV) infection, malignancy, sarcoidosis, TB treatment failure, TB treatment interruption, retreatment, or multi/extensively drug-resistant (MDR/XDR) TB were excluded. Patients with malignancy, HIV, and hepatitis B or C were

excluded as the occurrence of the above conditions may alter the presentation of TB disease due to immunosuppression.

Sampling

Assuming the proportion of smear grade + 1, 19.6% [6], based on 95% two-sided significance level (1-alpha), 80% power, and 9% margin of error, the representative sample size calculated (considering the local study by D'Souza et al.) was 73 patients using non-probability consecutive sampling.

Board Approval

This study was conducted after approval (No. F.2–81/2019-GENL/21153/JPMC) from the institutional ethical review board. Informed consent was obtained from all the patients for assigning them to the study and using their data in research.

Procedures and Investigations

A brief history of demographic data, duration of disease, comorbidities, and smoking habits was taken and recorded in a form. A person who smoked at least 100 cigarettes in his/her lifetime was labelled a *smoker* (according to Centers for Disease Control and Prevention https://www.cdc.gov/nchs/nhis/tobacco/tobacco_glossary.htm). All those who were known diabetics and on anti-diabetic treatment were considered as *diabetics*.

Chest X-ray findings (with regard to extent and cavitation) were also noted at diagnosis. Each participant's height (in meters) and weight (to the nearest kilogram) were measured. Every patient received weight-based anti-tubercular drug regimens (comprising isoniazid, rifampicin, ethambutol, and pyrazinamide) as recommended by the National TB Control Programme of Pakistan [19] (based on WHO Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update [20]). Drug compliance was evaluated (on compliance form) by confirmation from close relative of patient and retrieval of empty blister packs of prescribed drugs.

Patients' sputum was examined with microscopy and Xpert MTB/RIF (to rule out rifampicin resistance) before initiating treatment and with microscopy at 2 months of treatment. Sputum induction was done by means of 3% saline nebulization for patients who were unable to spontaneously produce sputum. The smears were prepared by the Ziehl–Neelsen method, examined for AFB by microscopy and graded according to the number of acid-fast bacilli (AFB) observed per high power field (HPF) as follows [21]:

- > 10 AFB per oil immersion field in 20 fields as 3 + positive
- 1–10 AFB per oil immersion field in 50 fields as 2 + positive
- 10–99 AFB per 100 oil immersion fields in 100 fields as 1 + positive
- 1–9 AFB per 100 oil immersion fields in 100 fields as sputum positive scanty

Data Analysis

Data were analyzed on SPSS (Statistical Package for Social Sciences) version 20.0. Mean and standard deviations were calculated for the quantitative variables like age, height, weight, and duration of tuberculosis. Frequencies and percentages were calculated for the qualitative variables like gender, BMI, socioeconomic status, occupational status, marital status, educational status, residential status, and clinical factors such as results of initial smear, chest X-ray extension, presence of chest X-ray cavities, smoking, and diabetes mellitus. Effect modifiers were controlled through stratification of age, gender, BMI, socioeconomic status, occupational status, marital status, and educational status to see the effect of these on outcome (smear positivity). Post stratification chi-square test was applied on stratified variables as well as the above-mentioned clinical factors associated with the persistent sputum positivity by taking p -value of ≤ 0.050 as statistically significant. Odds ratio was also calculated, and $OR > 1$ was considered significant.

Results

Males comprised the majority of the 73 patients ($n = 43$, 58.9%). Overall mean age of the patients was 38.6 ± 15.6 years. Less than half the participants ($n = 30$, 41.1%) had a normal BMI, with more than a third being underweight (37%). Most (58.9%) patients were literate to some extent, and all 73 patients belonged to lower to middle socioeconomic strata, which reflects the socioeconomic status of most, if not all, patients who visit public sector hospitals. Smokers constituted 61.6% ($n = 45$) of the study participants, whereas diabetics made up three-quarters ($n = 56$, 76.9%).

On initial sputum analysis, smear grade 3 + was the most common ($n = 30$, 41.1%), followed by 2 + ($n = 19$), scanty ($n = 15$), and 1 + ($n = 9$). A substantial number of patients had unilateral (61.6%), multilobar (60.3%) involvement on chest X-ray, while more than half ($n = 41$, 56.2%) had one or more cavities.

After 2 months of initiation of antitubercular drugs, 60 (82.2%) had negative follow-up sputum smears, whereas 13

(17.8%) were found to be sputum smear positive, of which 5 (6.8%) were scanty, 6 (8.2%) were 1+, and 2 (2.7) were 2+.

None of the demographic features (gender, age, BMI, occupation, education, marital status, and socio-economic status) was found to be significantly associated with persistent sputum positivity (Table 1). The proportion of smokers was less among non-converted as compared with converted group (30.8% vs. 40.0%, $p=0.754$), though not statistically significant (Table 2). Similarly, the differences with regard to diabetes and the extent of radiologic involvement between both groups were statistically unremarkable. Initial bacillary load as indicated by smear grade and Xpert burden did not predict sputum non-conversion ($p=0.460$ and 0.566 , respectively).

However, 84.6% of the non-converted patients had one or more cavities on chest radiograph (CXR) ($p=0.031$), while half the patients who converted had cavities. CXR cavitation was found in most patients with high initial smear grades, precisely 68.4% of those with grade 2+ and 60% of those with grade 3+, but this was statistically insignificant ($p=0.330$).

Further analysis by logistic regression revealed that CXR cavities were 5.5 times more likely to be associated with persistence of AFB on follow-up smears (OR = 5.5) as shown in Table 3.

Discussion

The proportion of patients whose sputum did not convert in our study was 17.8%, similar to other studies from the region (11.1% by Wang et al [22], 18% by Sheetal et al [5], 19.5% by D'Souza et al [6]). A few studies have shown relatively higher rates of non-conversion (25.3% by Dikitanas et al [23], 33.2% by Yellappa et al [24], 25.4% by Motao et al [25]).

All of the demographic variables including age, gender, and body mass index (BMI) were found to be non-significant in relation to smear positivity which is similar to the study by Bouti et al [10], who reported no association of age, sex, weight, alcoholism, addictions, and previous TB disease. In contrast, some studies have cited increasing age and/or male gender as predictors of sputum non-conversion [3, 6, 11, 23–25].

The presence of diabetes or smoking did not impact the rate of conversion at 2 months in the present study, a finding alike to many studies [10, 11, 23]. However, works by Babalik et al [12] and Sheetal et al [5] have shown that smokers are more likely to have delayed sputum conversion.

A multitude of studies [3, 6, 10, 22–26] have demonstrated the relationship between a high initial bacillary

Table 1 Association of sputum positivity with demographic characteristics

Factors		Total	Sputum converted ($n=60$)	Sputum non-converted ($n=13$)	Sig. ¹
Gender	Male	43 (58.9)	36 (60.0)	7 (53.8)	0.683
	Female	30 (41.1)	24 (40.0)	6 (46.2)	
Age (years)	Below 40	38 (52.1)	32 (53.3)	6 (46.2)	0.639
	40 or above	35 (47.9)	28 (46.7)	7 (53.8)	
BMI (kg/m^2) ²	< 18.5 (underweight)	27 (37.0)	22 (37.3)	5 (38.5)	0.989
	18.5–24.9 (normal)	30 (41.1)	24 (40.7)	5 (38.5)	
	≥ 25 (overweight)	16 (21.9)	13 (22.0)	3 (23.0)	
Occupation	Student	26 (35.6)	22 (36.7)	4 (30.8)	0.410
	Employed	28 (38.4)	21 (35.0)	7 (53.8)	
	Unemployed	19 (26.0)	17 (28.3)	2 (15.4)	
Education	Illiterate	30 (41.1)	24 (40.0)	6 (46.2)	0.411
	Primary	14 (19.2)	12 (20.0)	2 (15.4)	
	Secondary	20 (27.4)	15 (25.0)	5 (38.5)	
	Higher	9 (12.3)	9 (15.0)	0 (0)	
Marital status	Single	23 (31.5)	20 (33.3)	3 (23.1)	0.743
	Married	50 (68.5)	40 (66.7)	10 (76.9)	
Socio-economic status	Lower class	32 (43.8)	26 (43.3)	6 (46.2)	0.885
	Lower middle class	32 (43.8)	27 (45.0)	5 (38.5)	
	Middle class	9 (12.3)	7 (11.7)	2 (15.4)	

Values given in parentheses are percentages

¹Sig significance

²BMI body mass index

Table 2 Association of sputum positivity with environmental and clinical factors

Factors		Total	Sputum converted (<i>n</i> = 60)	Sputum non-converted (<i>n</i> = 13)	Sig. ¹
House	Own	43 (58.9)	35 (58.3)	8 (61.5)	0.831
	Rented	30 (41.1)	25 (41.7)	5 (38.5)	
Smoker	Yes	45 (61.6)	24 (40.0)	4 (30.8)	0.754
	No	28 (38.4)	36 (60.0)	9 (69.2)	
Diabetic	Yes	56 (76.7)	14 (23.3)	3 (23.1)	0.984
	No	17 (23.3)	46 (76.7)	10 (76.9)	
Initial smear	Scanty	15 (20.5)	14 (23.3)	1 (7.7)	0.460
	1 +	9 (12.3)	8 (13.3)	1 (7.7)	
	2 +	19 (26.0)	14 (23.3)	5 (38.5)	
	3 +	30 (41.1)	24 (40.0)	6 (46.2)	
Initial gen expert	Very low/trace	1 (1.4)	1 (1.7)	0 (0)	0.566
	Low	15 (20.5)	14 (23.3)	1 (7.7)	
	Medium	26 (35.6)	20 (33.3)	6 (46.2)	
	High	31 (42.5)	25 (41.7)	6 (46.2)	
CXR ² extension side	Unilateral	45 (61.6)	37 (61.7)	8 (61.5)	0.993
	Bilateral	28 (38.4)	23 (38.3)	5 (38.5)	
CXR extension lobes	Localized	29 (39.7)	24 (40.0)	5 (38.5)	0.918
	Multi-lobar	44 (60.3)	36 (60.0)	8 (61.5)	
CXR cavity	Present	41 (56.2)	30 (50.0)	11 (84.6)*	0.031
	Absent	32 (43.8)	30 (50.0)	2 (15.4)	

*Shows significantly higher proportion at 5% level of significance by using chi-square test

Values given in parentheses are percentages

¹Sig significance

²CXR chest radiograph

Table 3 Predicting factors of sputum smear positivity

Factors	Sputum converted (<i>n</i> = 60)	Sputum non-converted (<i>n</i> = 13)	OR ¹ (95% CI ²)	<i>p</i> -value
Male patients	36 (60.0)	7 (53.8)	0.78 (0.23–2.60)	0.683
Age > 40 years	32 (53.3)	6 (46.2)	1.33 (0.40–4.44)	0.639
BMI ³ < 18.5 kg/m ²	22 (37.3)	5 (38.5)	1.09 (0.28–4.28)	0.901
Employed	21 (35.0)	7 (53.8)	1.83 (0.47–7.19)	0.385
Illiterate	24 (40.0)	6 (46.2)	1.29 (0.38–4.30)	0.683
Married	40 (66.7)	10 (76.9)	1.67 (0.41–6.74)	0.474
Lower economic class	26 (43.3)	6 (46.2)	1.12 (0.34–3.74)	0.853
Own house	35 (58.3)	8 (61.5)	1.14 (0.33–3.91)	0.831
Smoking	24 (40.0)	4 (30.8)	0.67 (0.18–2.41)	0.537
Diabetes	14 (23.3)	3 (23.1)	0.99 (0.24–4.09)	0.984
3 + smear	24 (40.0)	6 (46.2)	1.29 (0.38–4.30)	0.683
CXR ⁴ bilateral sides	23 (38.3)	5 (38.5)	0.73 (0.21–2.56)	0.627
CXR multi-lobe extension	36 (60.0)	8 (61.5)	1.07 (0.31–3.65)	0.918
CXR cavity	30 (50.0)	11 (84.6)*	5.50 (1.12–27.0)	0.035

*Shows significantly higher proportion at 5% level of significance

¹OR odds ratio

²CI confidence interval

³BMI body mass index

⁴CXR chest radiograph

load (smear grade 3+) and likelihood of persistent sputum positivity, though our study has shown no such association ($p=0.683$, OR 1.29, 95% CI 0.38–4.30).

Radiologic extent of disease has been reported by several studies as being a predictor of sputum non-conversion [10, 12, 23]. This includes the involvement of a greater number of lobes, cavitation, and/or military disease. We investigated the extent (unilateral/bilateral and multilobar) of disease but found no association with persistent sputum positivity. However, the presence of one or more cavities (OR = 5.50, CI 1.12–27.0; $p=0.035$) strongly predicted non-conversion of sputum at 2 months. Our finding is corroborated by similar reports from other studies [3, 11, 22, 23] that have also documented cavitation as a predictor of persistent sputum positivity. Interestingly, half of our patients who did convert also had one or more cavities on the CXR.

A limitation of the present study is the use of smear microscopy for follow-up (albeit in accordance with WHO guidelines [20] and the local TB Control Programme [19]) at 2 months. Ideally, it is the negative cultures that truly reflect sputum conversion but getting cultures is less cost-effective and more time-consuming and therefore not feasible. Since the microscopy also reports non-viable bacteria, its correlation with culture (which is the gold standard) is debatable; a German study [27] has reported a strong correlation between smear microscopy and time to culture positivity within the first 2 months of treatment. The same holds true for Xpert MTB/RIF, a rapid, easily available nucleic acid amplification test; its ability to detect non-viable bacilli with greater sensitivity precludes its use as a follow-up tool.

An understanding of the relevance of these factors pertaining to persistent sputum positivity can help clinicians foresee which patients will remain infectious for a longer period of time and may have worse outcomes. This stratification may also improve large-scale TB control activities. The current study sets a precedent for future much larger studies at national level that could also draw conclusions about outcomes at the end of treatment and occurrence of relapse. Previous studies have highlighted the association between high smear grades and treatment failure/relapse [26–28].

Conclusion

Our study shows that the presence of one or more cavities can strongly predict ($p=0.035$) sputum non-conversion at 2 months and thus flag patients who may be at risk for poor outcomes. One of the key measures in making TB treatment and control activities a success is identifying patients at high risk of transmission and poor outcomes. The recognition of individuals at high risk of non-conversion through the use of chest radiograph (which is done across all TB centers, even in low-income countries) would help national TB control

programs focus their resources (strict monitoring and DOT) towards care for these particular patients.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s42399-021-01098-6>.

Author Contribution Nadia Jawad: Acquisition and analysis of data and drafting the work.

Saira Jafri: Analysis and interpretation of data and revising the manuscript critically for important intellectual content.

Nausheen Saifullah: Final approval of the version to be published.

Naseem Ahmed: Revising the work critically and supervision.

Availability of Data and Material N/A.

Code Availability N/A.

Declarations

Ethics Approval Taken from JPMC Institutional Review Board Committee on June 10, 2019.

Consent to Participate An informed consent for participation was taken from either the patient themselves or the attendant, whichever was possible.

Consent for Publication N/A.

Conflict of Interest The authors declare no competing interests.

References

1. World Health Organization. Tuberculosis Factsheets. March 2020. Available from <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>.
2. Parikh R, Nataraj G, Kanade S, Khatri V, Mehta P. Time to sputum conversion in smear positive pulmonary TB patients on category I DOTS and factors delaying it. *J Assoc Physicians India*. 2012 Aug;60(8):22–6.
3. Singla R, Osman MM, Khan N, Al-Sharif N, Al-Sayegh MO, Shaikh MA. Factors predicting persistent sputum smear positivity among pulmonary tuberculosis patients 2 months after treatment. *Int J Tuberc Lung Dis*. 2003 Jan 1;7(1):58–64.
4. Tiwari S, Kumar A, Kapoor SK. Relationship between sputum smear grading and smear conversion rate and treatment outcome in the patients of pulmonary tuberculosis undergoing dots—a prospective cohort study. *Indian J Tuberc*. 2012 Jul;59(3):135–40.
5. Vora SD, Gandhi RV, Vasava SA, Ganava AR, Amin G. A study of factors affecting sputum conversion in patients of pulmonary tuberculosis. *Natl J Community Med*. 2016; 7(2): 142–146. <http://www.njcmindia.org/home/download/792>.
6. D'Souza KA, Zaidi SM, Jaswal M, Butt S, Khowaja S, Habib SS, et al. Factors associated with month 2 smear non-conversion among category 1 tuberculosis patients in Karachi, Pakistan. *J Infect Public Health*. 2018 Mar 1;11(2):283–5. <https://doi.org/10.1016/j.jiph.2017.06.009>.
7. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. *Lancet Infect Dis*. 2010 Jun 1;10(6):387–94. [https://doi.org/10.1016/S1473-3099\(10\)70071-2](https://doi.org/10.1016/S1473-3099(10)70071-2).

8. Fortún J, Martín-Dávila P, Molina A, Navas E, Hermida JM, Cobo J, et al. Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation? *J Antimicrob Chemother.* 2007 Apr 1;59(4):794–8. <https://doi.org/10.1093/jac/dkm025>.
9. Unsematham S, Kateruttanakul P. Factors predicting sputum smear conversion and treatment outcomes in new smear-positive pulmonary tuberculosis. *J Med Assoc Thailand= Chotmaihet thangphaet.* 2013;96(6):644. <https://pubmed.ncbi.nlm.nih.gov/23951819/>.
10. Bouti K, Aharmim M, Marc K, Soualhi M, Zahraoui R, Benamor J, et al. Factors influencing sputum conversion among smear-positive pulmonary tuberculosis patients in Morocco. *ISRN Pulmonol.* 2013 Jun;27:2013. <https://doi.org/10.1155/2013/486507>.
11. Dominguez-Castellano A, Muniain MA, Rodriguez-Bano J, Garcia M, Rios MJ, Galvez J, Perez-Cano R. Factors associated with time to sputum smear conversion in active pulmonary tuberculosis. *The Int J Tuberc Lung Dis.* 2003;7(5):432–8. <https://www.ingentaconnect.com/content/iatld/ijtld/2003/00000007/00000005/art00007>.
12. Babalik A, Kiziltas S, Arda H, Oruc K, Celintas G, Calalettin H. Factors affecting smear conversion in tuberculosis management. *Med Sci.* 2012;1(4):351–62. <https://doi.org/10.5455/medscience.2012.01.8036>.
13. Moderbacher CR, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, Belanger S, Abbott RK, Kim C, Choi J, Kato Y. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. *Cell.* 2020 Nov 12;183(4):996–1012.
14. Sheerin D, Abhimanyu XW, Johnson WE, Coussens A. Systematic evaluation of transcriptomic disease risk and diagnostic biomarker overlap between COVID-19 and tuberculosis: a patient-level meta-analysis. *medRxiv.* 2020.
15. Tadolini M, Codecasa LR, García-García JM, Blanc FX, Borisov S, Alffenaar JW, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. *Eur Respir J.* 2020;56(1). 2021;25(1). <https://doi.org/10.5588/ijtld.20.0786>.
16. TB/COVID-19 Global Study Group. TB and COVID-19 co-infection: rationale and aims of a global study. *Int J Tuberc Lung Dis.* 2021;25(1). <https://doi.org/10.5588/ijtld.20.0786>.
17. Stochino C, Villa S, Zucchi P, Parravicini P, Gori A, Raviglione MC. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. *Eur Respir J.* 2020;56(1):2001708. <https://doi.org/10.1183/13993003.01708-2020>.
18. Migliori GB, Thong PM, Akkerman O, Alffenaar JW, Álvarez-Navascués F, Assao-Neino MM, et al. Worldwide effects of coronavirus disease pandemic on tuberculosis services, January–April 2020. *Emerg Infect Dis.* 2020;26(11):2709–12. <https://doi.org/10.3201/eid2611.203163>.
19. National Tuberculosis Control Program. National guidelines for the control of tuberculosis in Pakistan (revised 2019). 2019. Available from: http://ntp.gov.pk/ntp-old/uploads/National_Guidelines_for_TB_Revised_2019.pdf.
20. World Health Organization. WHO Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017update). 2017. Available from: <http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf?ua=1>.
21. World Health Organization. Mycobacteriology Laboratory Manual. April 2014. Available from: <https://www.who.int/tb/laboratory/mycobacteriology-laboratory-manual.pdf>.
22. Wang JY, Lee LN, Yu CJ, Chien YJ, Yang PC, Tami Group. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis. *Respirology.* 14(7):1012–9. <https://doi.org/10.1111/j.1440-1843.2009.01598.x>.
23. Diktanas S, Vasiliauskiene E, Polubenko K, Danila E, Celedinaite I, Boreikaite E, et al. Factors associated with persistent sputum positivity at the end of the second month of tuberculosis treatment in Lithuania. *Tuberc Respir Dis.* 2018;81(3):233–40. <https://doi.org/10.4046/trd.2017.0096>.
24. Yellappa V, Kandpal V, Lall D, Tabassum A. Determinants of sputum conversion at two months of treatment under National Tuberculosis Programme, South India. *Int J Med Sci Public Health.* 2016;12(1). https://www.academia.edu/download/48328166/Determinants_of_sputum_conversion.pdf.
25. Mota PC, Carvalho A, Valente I, Braga R, Duarte R. Predictors of delayed sputum smear and culture conversion among a Portuguese population with pulmonary tuberculosis. *Revista Portuguesa de Pneumologia (English Edition).* 2012 Mar 1;18(2):72–9. <https://doi.org/10.1016/j.rppnen.2012.01.004>.
26. Nwokeukwu HI, Awujo DN, Emma-Ukeagbu U. Association of sputum conversion and outcome with initial smear grading among new smear positive Tuberculosis patients in a Tertiary Health Facility, South East Zone, Nigeria. *J Dent Med Sci.* 2013;4(6):2279–0853. <http://iosrjournals.org/iosr-jdms/papers/Vol4-issue6/B0460409.pdf>.
27. Oлару ID, Heyckendorf J, Grossmann S, Lange C. Time to culture positivity and sputum smear microscopy during tuberculosis therapy. *PLoS One.* 2014;9(8):e106075. <https://pdfs.semanticscholar.org/0091/55c8ac859386aa41cd86b7935abf2382dddd.pdf>.
28. Hesselting AC, Walzl G, Enarson DA, Carroll NM, Duncan K, Lukey PT et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. *The international journal of tuberculosis and lung disease.* 2010;14(5):560–70. <https://pubmed.ncbi.nlm.nih.gov/20392348/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.